Key Points GAAP loss per share of $0.55 in Q2 2025 beat analyst estimates by $1.13. GAAP revenue of $5.5 million in Q2 2025 missed expectations by 26%. Advanced key clinical programs, with first U.S.

Obstructive sleep apnea severity measured via apnea-hypopnea index decreased among patients receiving AD109, an oral ...

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor ...

Aurinia Pharmaceuticals Inc. achieved record Lupkynis sales of $66.6M in Q2 while managing cash flow. Click for insights on ...

Lantheus Holdings (NASDAQ:LNTH) announced on Wednesday that the U.S. Food and Drug Administration (FDA) accepted its ...

US FDA clears Hemispherian’s IND application for first-in-class glioblastoma therapeutic, GLIX1: Oslo, Norway Wednesday, August 6, 2025, 15:00 Hrs [IST] Hemispherian AS, a pione ...

Q2 2025 net product revenue for ZORYVE® (roflumilast) was $81.5 million, a 164% increase compared to Q2 of 2024, and a 28% increase compared to Q1 of 2025, driven by strong portfolio demand ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

On July 23, Andrew Bushell, the council’s licensing officer, revealed details behind the 21 complaints he’d received ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL: Princeton, New Jersey Wednesday, August 6, 2 ...